Study identification

EU PAS number

EUPAS5383

Study ID

11823

Official title and acronym

CAncer Risk and INsulin analoGues (CARING) project

DARWIN EU® study

No

Study countries

Denmark
Finland
Netherlands
Norway
Sweden

Study description

The CARING (CAncer Risk and INsulin analoGues) project will obtain precise data on the incidence of cancer in diabetic patients and determine any link with use of various insulin and insulin analogues. The study will utilise high quality prescription databases and other national data sources, integrated at European level with advanced methods of harmonising data. The study will take into account potential confounders. The project aims to determine the influence of drug dose on risk, and through a risk model, identify predictors of cancer for insulin users. A review of published evidence combined with a study of tumour characteristics and gene expression in breast cancer tumour collections will aid understanding of potential mechanisms of cancer initiation and/or promotion by insulin.

Study status

Finalised
Research institutions and networks

Institutions

Tampere University Hospital
Finland
First published:
01/02/2024
Institution Educational Institution Hospital/Clinic/Other health care facility
Aarhus University Hospital Aarhus, Denmark, University of Tampere Tampere, Finland, University of Helsinki Helsinki, Finland, Netherlands Cancer Institute Amsterdam, Netherlands

Networks

Contact details

Marie L De Bruin

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
EU institutional research programme

More details on funding

FP7 HEALTH.2011.4.2-2
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable